Stifel Financial Corp Has $6.83 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Stifel Financial Corp increased its stake in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 54.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,319 shares of the medical research company’s stock after acquiring an additional 32,425 shares during the period. Stifel Financial Corp’s holdings in Exact Sciences were worth $6,830,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Artisan Partners Limited Partnership raised its stake in shares of Exact Sciences by 12.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock valued at $330,711,000 after purchasing an additional 508,764 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Exact Sciences by 11.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock worth $137,483,000 after buying an additional 192,372 shares in the last quarter. Norges Bank acquired a new stake in Exact Sciences in the 4th quarter valued at approximately $120,308,000. Jennison Associates LLC lifted its stake in Exact Sciences by 94.0% in the 4th quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock valued at $100,681,000 after acquiring an additional 659,235 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Exact Sciences by 2.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,167,909 shares of the medical research company’s stock worth $86,402,000 after acquiring an additional 30,831 shares during the last quarter. 88.82% of the stock is owned by institutional investors.

Exact Sciences Stock Down 3.9 %

EXAS opened at $42.93 on Friday. The stock’s fifty day simple moving average is $58.89 and its 200 day simple moving average is $62.77. Exact Sciences Co. has a 1-year low of $42.72 and a 1-year high of $100.77. The stock has a market cap of $7.92 billion, a PE ratio of -32.52 and a beta of 1.26. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66.

Exact Sciences (NASDAQ:EXASGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). The firm had revenue of $637.52 million for the quarter, compared to the consensus estimate of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. As a group, research analysts expect that Exact Sciences Co. will post -1.15 earnings per share for the current year.

Insider Buying and Selling at Exact Sciences

In other news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at $69,544,888.65. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of Exact Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now owns 71,787 shares in the company, valued at approximately $5,025,090. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the sale, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. Insiders have sold a total of 5,498 shares of company stock valued at $370,105 in the last three months. 1.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on EXAS. Canaccord Genuity Group cut their price objective on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. BTIG Research cut their price target on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. William Blair restated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. TheStreet lowered Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Finally, Citigroup decreased their price target on Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.07.

Get Our Latest Stock Report on EXAS

Exact Sciences Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.